https://youtube.com/RpMEMX-c7VU?t=7
https://youtube.com/RpMEMX-c7VU?t=7
We reviewed computerized tomograms (CT) for basal ganglia and dentate nucleus calcifications in 79 patients with Parkinson’s disease (PD), 54 patients with Alzheimer’s disease (AD) and 109 controls aged 50 or more. When it was determined, no patient had disturbances in calcium metabolism. We found: …
Pharma company also plans to investigate psychedelic therapies for multiple sclerosis
Source: Researchers focus on use of psilocybin to treat Parkinson’s disease
In this article, our experts discuss the potential applications for a Parkinson’s Disease simulator to inform decision-making and strategic planning early in the development of disease modifying therapies (DMTs)
Source: White Paper | Modeling DMT Strategies for Parkinson’s Disease | Evidera
Stem cell therapy for autism, cerebral palsy, heart failure, multiple sclerosis, osteoarthritis, rheumatoid arthritis, and spinal cord injury.
Source: Stem Cell Institute Panama – Stem Cell Therapy – Stem Cell Institute
Fountain Life brings together the world’s most renowned medical and health experts to boost longevity and performance. Our goal is to educate our members and empower them to be proactive about their health. We help our members operate at peak performance throughout their lifespan! We strive to help our members make 100 the new 60.
A chronic progressive CNS disorder characterized by slowness of purposeful movement, resting tremors, and muscle rigidity. Also called “Parkinsonism” and “Paralysis Agitans” Dorland’s Medical Dictionary describes the Parkinsonian complex as “neurologic disorders characterized by hypokinesia, tremors and muscular rigidity. It typically occurs late in life, although juvenile forms have been described.” The diagnosis for their disorder is made from the
Source: Ecopolitan – Parkinson’s Disease – Functional medicine – Dr. Adiel Tel-Oren
92 patients with Parkinson’s disease not previously treated with levodopa were considered as eligible for this triple-blind trial. Patients were allocated at random to treatment with either levodopa + benserazide ratio 4:1 (Madopar) or levodopa + carbidopa ratio 10:1 (Sinemet) using dosage schedules …
Source: Parkinson’s disease treated with Sinemet or Madopar. A controlled multicenter trial – PubMed
Rasagiline is a novel, potent, and selective MAO-B inhibitor shown to be effective for Parkinson’s disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50-75 mg) were perf …
Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans
Source: Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans: Cell Reports
Dietary Plant Lectins Appear to Be Transported from the Gut to Gain Access to and Alter Dopaminergic Neurons of Caenorhabditis elegans, a Potential Etiology of Parkinson’s Disease
Results: Skin biopsies provide >90% sensitivity and >90% specificity to distinguish PD from control participants across all biopsies sites with quantification of either pilomotor or sudomotor α-synuclein deposition. All individuals with PD have significantly higher cutaneous α-synuclein deposition than control participants, even those individuals with PD and no evidence of autonomic dysfunction. Deposition of α-synuclein is most prominent in sympathetic adrenergic nerve fibers innervating the arrector pili muscles, but is also present in sudomotor (sympathetic cholinergic) nerve fibers. α-Synuclein is present even in the early stages of disease and disease of short duration. α-Synuclein ratios were higher in individuals with autonomic failure, with more advanced stages of disease and disease of longer duration.Conclusions: The α-synuclein ratio provides a sensitive and specific diagnostic biomarker of PD even in patients without autonomic failure.Classification of evidence: This study provides Class III evidence that cutaneous α-synuclein deposition accurately identifies patients with PD.
Source: The diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson disease – PMC
ognitive benefit of acute WGOE supplementation does not persist with chronic treatment
Seems that cognitive benefit of green oat supplementation does not persist over time
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson’s Disease – Full Text View.
For Indians, it appears that it would be most prudent to have a diet with about 50 per cent carbohydrate (using complex carbs and whole grains such as brown rice or whole wheat) about 20-25 per cent protein (preferably from vegetable proteins such as legumes and pulses) and the remaining 25-30 per cent from healthy fats like monounsaturated fats (e.g. groundnut oil or mustard oil and nuts and seeds) along with plenty of green leafy vegetables. Such a diet may not immediately give dramatic results as far as weight reduction is concerned. However, it will be sustainable in the long term and will be less risky and certainly more healthy and also help prevent non-communicable diseases such as diabetes, cardiovascular disease and certain cancers.
Scientists recently tested probiotics in a roundworm model of Parkinson’s. A particular bacterium had a protective effect and improved symptoms.